Grünenthal GmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.grunenthal.com
Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 450
- Registration Number
- NCT05449132
- Locations
- 🇺🇸
Achieve Clinical Research, LLC, Birmingham, Alabama, United States
🇺🇸Arizona Arthritis and Rheumatology Associates (AARA) P.C, Glendale, Arizona, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 930
- Registration Number
- NCT05377489
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Associates (AARA) P.C, Glendale, Arizona, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Orange County Research Institute, Anaheim, California, United States
Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 450
- Registration Number
- NCT05248386
- Locations
- 🇨🇿
Db Ortopedie s.r.o, Pribram, Czechia
🇩🇪Ortho-Zentrum Karlsruhe, Karlsruhe, Germany
🇮🇹Universita degli Studi della Campania Luigi Vanvitelli - Azienda Ospedaliera Universitaria, Naples, Italy
Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections
- Conditions
- PharyngitisBronchitisOtitis MediaTonsillitis
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 265
- Registration Number
- NCT04016051
- Locations
- 🇩🇪
DE11, Balve, Germany
🇩🇪DE10, Beckum, Germany
🇩🇪DE09, Hameln, Germany
Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
- Conditions
- Pharmacokinetic
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 32
- Registration Number
- NCT03979989
- Locations
- 🇧🇪
J&JPRD Clinical Pharmacology Unit, Merksem, Belgium
Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT03956134
- Locations
- 🇩🇪
Department of Clinical Pharmacology, Grünenthal GmbH, Aachen, Germany
Investigation How CG5503 is Taken up and Excreted From the Body After 2 Minutes Intravenous Infusion With and Without Oral Co-administration of Charcoal
- Conditions
- Pharmacokinetic
- Interventions
- Drug: 4 ml CG5503Drug: 5 g charcoal powder
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT03951987
- Locations
- 🇩🇪
Department of Clinical Pharmacology Grünenthal GmbH, Aachen, Germany
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
- Conditions
- Prolonged QTc IntervalPharmacokinetic
- Interventions
- Drug: 100 mg CG5503 (tapentadol hydrochloride) PR tabletDrug: Placebo matching CG5503 PR tabletDrug: Placebo matching moxifloxacin capsuleDrug: 400 mg Moxifloxacin tablet (overencapsulated)
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT03951402
- Locations
- 🇩🇪
DE001 - Contract research organisation, Neuss, Germany
A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions
- Conditions
- Bioavailability
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Grünenthal GmbH
- Registration Number
- NCT03905564
Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch
- Conditions
- Pain
- Interventions
- Drug: Matching placebo patch to T1Drug: Matching placebo patch to RDrug: Matching placebo patch to T2
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 47
- Registration Number
- NCT03785613
- Locations
- 🇨🇭
Swiss Pharma Contract, Allschwil, Switzerland